Fosun Pharma Advances Clinical Trials for Innovative Respiratory Drug

Confident Investing Starts Here:

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has provided an update.

Shanghai Fosun Pharmaceutical announced the progress of a Phase II clinical trial for XH-S004 tablets, developed by its subsidiary Zhejiang Xinghao Pengbo Pharmaceutical Co., Ltd., for treating non-cystic fibrosis bronchiectasis in China. The drug, a small molecule oral DPP-1 inhibitor, is also being tested for chronic obstructive pulmonary disease, with clinical trials approved in China. The company has invested approximately RMB 61 million in the R&D of XH-S004 as of April 2025, highlighting its commitment to advancing treatment options in respiratory diseases.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, focusing on the pharmaceutical industry. The company is involved in the development and production of various pharmaceutical products, with a particular emphasis on innovative drug research and development.

Average Trading Volume: 4,672,541

Technical Sentiment Signal: Hold

Current Market Cap: HK$62.27B

See more data about 2196 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks’

Best Online Brokers

, and find the ideal broker for your trades.

Report an Issue

No Byline Policy

Editorial Guidelines

Corrections Policy

Source